Cell Therapies for Acute Radiation Syndrome

Barbara A. Christy,Maryanne C. Herzig,Xiaowu Wu,Arezoo Mohammadipoor,Jennifer S. McDaniel,James A. Bynum
DOI: https://doi.org/10.3390/ijms25136973
IF: 5.6
2024-06-27
International Journal of Molecular Sciences
Abstract:The risks of severe ionizing radiation exposure are increasing due to the involvement of nuclear powers in combat operations, the increasing use of nuclear power, and the existence of terrorist threats. Exposure to a whole-body radiation dose above about 0.7 Gy results in H-ARS (hematopoietic acute radiation syndrome), which is characterized by damage to the hematopoietic system; higher doses result in further damage to the gastrointestinal and nervous systems. Only a few medical countermeasures for ARS are currently available and approved for use, although others are in development. Cell therapies (cells or products produced by cells) are complex therapeutics that show promise for the treatment of radiation injury and have been shown to reduce mortality and morbidity in animal models. Since clinical trials for ARS cannot be ethically conducted, animal testing is extremely important. Here, we describe cell therapies that have been tested in animal models. Both cells and cell products appear to promote survival and lessen tissue damage after whole-body irradiation, although the mechanisms are not clear. Because radiation exposure often occurs in conjunction with other traumatic injuries, animal models of combined injury involving radiation and future countermeasure testing for these complex medical problems are also discussed.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?